Key Takeaway: Cognition Therapeutics is preparing to initiate a Phase 3 clinical trial for its Alzheimer's drug. The announcement indicates the company's ongoing commitment to addressing Alzheimer's disease through advanced clinical research. Further details regarding the trial's design and objectives have not been disclosed.
Price reaction · baseline $1.61 (2025-12-02 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close · peak
+11.8%
day 1
+9.3%
day 3
+8.7%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.